drugset / Trial / NCT07229664

Vinpocetine in Patients With Parkinsonian Disease

NCT07229664 ↗

Phase 2/3 Recruiting 60 enrolled Tanta University
RandomizedParallel-groupDouble-blindTreatment

Summary

The clinical manifestations of Parkinson's disease (PD), a chronic neurodegenerative condition, include resting tremor, hypokinesia, bradykinesia, stiffness and postural instability. These motor symptoms are caused by a selective loss and degeneration of dopaminergic neurons in the substantia nigra pars compacta (SNpc) region, which leads to a dopamine (DA) insufficiency in the striatum

Timeline

Start
2025-11-10
Primary completion
2026-11-20
Completion
2027-11-20

Drugs

EvaluationDrugModalityDoseRoute
Comparator Vinpocetine Small molecule 10 mg —
Comparator Carbidopa Unknown 12.5 mg —
Comparator Levodopa Unknown 125 mg —

Indications